FDA agrees to implement AADA’s iPLEDGE recommendations
The FDA agreed to require significant Academy-recommended changes to the iPLEDGE program that will alleviate administrative burdens for dermatologists. The AADA has been fighting for these changes since 2021 when the FDA transitioned to a new iPLEDGE platform that malfunctioned and disrupted treatment for many patients.